Paul R. Fonteyne
Director/Board Member at AMYLYX PHARMACEUTICALS, INC.
Net worth: 279 184 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Justin Klee | M | 34 | 11 years | |
| Josh Cohen | M | 33 | 11 years | |
| Lawrence G. Miller | M | 70 |
Apnimed, Inc.
 Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Isaac Cheng | M | 49 |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 8 years |
| George Milne | M | 80 | 9 years | |
| Stephen Bloch | M | 62 |
Allyx Therapeutics, Inc.
 Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | 4 years |
| Pradeep Kumar Khosla | M | 67 |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 41 years |
| Glenn Marina | M | - |
Revelar Biotherapeutics, Inc.
 Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | - |
| Robert McNeil | M | 81 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Simon Michel | M | 47 | 18 years | |
| Michael Zaugg | M | 52 | 7 years | |
| Fouzia Laghrissi-Thodes | M | 61 |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | 6 years |
| Ulrike Bauer | F | 55 | 21 years | |
| Royston Glasspool | M | 61 |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | 7 years |
| Daphne Quimi | F | 58 | 3 years | |
| Luigi Taranto Montemurro | M | - |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 7 years |
| Katie Sullivan | F | - | 4 years | |
| Henry d'Abo | M | - |
DalCor Pharma UK Ltd.
 DalCor Pharma UK Ltd. BiotechnologyHealth Technology Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology.
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Gilbert Achermann | M | 60 | 4 years | |
| Martin C. Münchbach | M | 54 | 5 years | |
| Timothy Siegert | M | - |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | - |
| Rody Yared | M | - |
DalCor Pharma UK Ltd.
DalCor Pharma UK Ltd. BiotechnologyHealth Technology Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology.
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Dennis Patrick Molnar | M | 55 |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | - |
| Kari Firestone | F | - | 1 years | |
| Rudy Tanzi | M | - | 10 years | |
| Thomas Kutt | M | - | - | |
| Gina Mazzariello | F | 53 | 2 years | |
| Bekki Kidd | F | 55 | 3 years | |
| Domitille de Vienne | F | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Lindsey Allen | F | - | - | |
| Jim Frates | M | 56 | 3 years | |
| Frank Mengis | M | 60 | 9 years | |
| David Scheer | M | - |
Revelar Biotherapeutics, Inc.
Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | - |
| Michelle Bonfilio | F | 53 | 2 years | |
| Stefan Mathias Larson | M | 48 |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 2 years |
| Stephen M. Strittmatter | M | - |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | - |
| Gregory Ho | M | 71 |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | - |
| Joseph Avellone | M | 76 |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | - |
| Mark L. Smith | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Andrew Coxhead | M | 56 | 3 years | |
| Robert A. Bettigole | M | - |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | - |
| Kathryn Cavanaugh | F | 50 | 2 years | |
| Serge Langford | M | - |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | - |
| Chris Dimitropoulos | M | 45 |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 2 years |
| Ron Farkas | M | - |
Apnimed, Inc.
Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yishai Zohar | M | 61 | 1 years | |
| Elliot Maltz | M | 39 | 8 years | |
| David Abraham | M | 58 | 2 years | |
| Edward Myles | M | 52 | 4 years | |
| William Heiden | M | 64 | 8 years | |
| Raju S. Kucherlapati | M | 81 | 7 years | |
| Pradeep K. Khosla | M | 67 |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 30 years |
| Grégory Behar | M | 55 |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany.
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | 4 years |
| Dominic Anthony Charles Perks | M | 47 | 2 years | |
| Joan Mannick | M | 66 | 4 years | |
| Marla Persky | F | 68 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 8 years |
| Jane Wildman | F | 63 | 2 years | |
| Scott Myers | M | 57 | - | |
| Philip Laskaway | M | 82 | 3 years | |
| Gino Santini | M | 66 | 8 years | |
| J. Carroll | M | 74 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 9 years |
| Edward M. McNamara | M | 59 | 3 years | |
| Wolfgang Baiker | M | - |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | 2 years |
| Jennifer Robinson | F | - | - | |
| Alison Bauerlein | F | 42 | 1 years | |
| David Johnson | M | 41 | 1 years | |
| Elaine Chiquette | M | 58 | 6 years | |
| Kathrine O'Brien | F | 61 | 1 years | |
| Desiree Ralls-Morrison | F | 57 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 4 years |
| Lloyd Klickstein | M | 67 | - | |
| Michael Herrman | M | 56 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 16 years |
| Michael Grissinger | M | 70 | 2 years | |
| Wendy Hufford | F | 62 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 3 years |
| Hemant Bharat Ram | M | 58 |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 6 years |
| David Pass | M | 56 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | 9 years |
| Stewart Abbot | M | 57 | - | |
| Mark J. Manoff | M | 67 | 3 years | |
| Steve Hoover | M | 63 |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 8 years |
| Barbara H. Deptula | F | 69 | 7 years | |
| Deborah Ellinger | F | 65 | 3 years | |
| Jamey Seely | F | 53 | 1 years | |
| Sandra Helton | F | 74 | 3 years | |
| Sandra Peterson | F | 65 | 2 years | |
| Wilhelm Michel | M | 77 | 19 years | |
| John LaMattina | M | 74 | 9 years | |
| Davey Scoon | M | 78 | 14 years | |
| Sharon Wienbar | F | 62 | 2 years | |
| Clayton Christopher | M | 51 | 1 years | |
| Peter N. Handrinos | M | - |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 6 years |
| Fred J. Goff | M | - |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 5 years |
| David Steinberg | M | 52 | 3 years | |
| Marco Racanelli | M | 57 |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 4 years |
| Jon B. Stark | M | - |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 5 years |
| Harry Leider | M | 66 | 4 years | |
| Beat Maurer | M | 66 | 20 years | |
| Jacques Benkoski | M | - |
Carnegie Mellon University
Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | 4 years |
| Alessandro Sannino | M | 52 | 15 years | |
| Wolfram Carius | M | 63 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | - |
| Ravi Sachdev | M | 47 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 82 | 82.83% |
| Switzerland | 9 | 9.09% |
| Canada | 8 | 8.08% |
| United Kingdom | 2 | 2.02% |
| Germany | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul R. Fonteyne
- Personal Network
